Literature DB >> 1111662

Platelet adhesiveness and aggregation in congenital afibrinogenemia. An investigation of three patients with post-transfusion, cross-correction studies between two of them.

A Girolami, L De Marco, L Virgolini, R Peruffo, F Fabris.   

Abstract

Platelet adhesiveness and aggregation were studied in three patients with congenital afibrinogenemia. The results obtained may be summarized as follows: The retention of platelets to a glass-bead filter determined with the Salzman method was significantly decreased; it was normal after fibrinogen infusion. With a modification of the Hellem test the values obtained were slightly decreased. Adrenalin-induced aggregation was absent whereas ADP-and collagen-induced aggregation was near normal or slightly decreased. Thrombofax aggregation was absent in citrated plasma. The abnormalities of platelet aggregation were corrected after fibrinogen infusion or after addition in vitro of fibrinogen, hemofilia A plasma and PPP obtained from an afibrinogenemic patient after fibrinogen infusion. The abnormalities of platelet aggregation were corrected well by ADP, collagen and Thrombofax in heparinized blood, but only a slight correction of adrenalin-induced aggregation was noted. Thrombin aggregation proved to be normal with the higher concentrations, whereas it was defective with the lower ones. Ristocetin aggregation was normal in citrated plasma at the concentration of 1.5 mg per ml but it was absent at the lower concentration (1.0 mg per ml). Ristocetin aggregation was, on the other hand absent in heparinized blood regardless of the concentration. These findings are in agreement with the presence of a prolonged bleeding time in congenital afibrinogenemia and suggest that fibrinogen plays an important role in platelet aggregation and adhesiveness.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1111662     DOI: 10.1007/bf01633963

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  34 in total

1.  MEASUREMENT OF PLATELET ADHESIVENESS. A SIMPLE IN VITRO TECHNIQUE DEMONSTRATING AN ABNORMALITY IN VON WILLEBRAND'S DISEASE.

Authors:  E W SALZMAN
Journal:  J Lab Clin Med       Date:  1963-11

2.  THE AGGREGATION OF BLOOD PLATELETS.

Authors:  G V BORN; M J CROSS
Journal:  J Physiol       Date:  1963-08       Impact factor: 5.182

3.  A report of a case of congenital afibrinogenemia.

Authors:  A Girolami; R Venturelli; G Bareggi
Journal:  Blut       Date:  1972-01

4.  Ristocetin--a new tool in the investigation of platelet aggregation.

Authors:  M A Howard; B G Firkin
Journal:  Thromb Diath Haemorrh       Date:  1971-10-31

5.  An attempt to assay the 'Anti-Willebrand Factor'.

Authors:  A B Chandler; H Stormorken; N O Solum; A Gaarder
Journal:  Scand J Clin Lab Invest       Date:  1965       Impact factor: 1.713

6.  Need of fibrinogen for thrombin-induced aggregation of porcine platelets.

Authors:  K M Brinkhous; M S Read; N F Rodman; R G Mason
Journal:  J Lab Clin Med       Date:  1969-06

7.  [Diagnostic and therapeutic problems in congenital afibrinogenemia].

Authors:  R Egbring; K Andrassy; H Egli; J Meyer-Lindenberg
Journal:  Blut       Date:  1971-04

8.  Congenital thrombocytopathy (platelet factor 3 defect) with prolonged bleeding time but normal platelet adhesiveness and aggregation.

Authors:  A Girolami; A Brunetti; D Fioretti; E Gravina
Journal:  Acta Haematol       Date:  1973       Impact factor: 2.195

9.  Platelet function in congenital afibrinogenemia.

Authors:  E Gugler; E F Lüscher
Journal:  Thromb Diath Haemorrh       Date:  1965-11-15

10.  [Measurement of platelet aggregation. Anti-aggregating activity of heparin].

Authors:  J Aznar
Journal:  Hemostase       Date:  1966
View more
  5 in total

1.  The effect of heparin on platelet aggregation by common inductors and by ristocetin in congenital bleeding disorders due to factor VIII or fibrinogen defects.

Authors:  A Girolami; L De Marco; L Virgolini; R Peruffo; F Fabris
Journal:  Blut       Date:  1975-10

2.  Failure of ellagic acid to affect platelet aggregation in normal and in factor XII deficient plasma.

Authors:  A Girolami; L Virgolini; R Peruffo; L de Marco
Journal:  Blut       Date:  1975-08

3.  Type IIB von Willebrand factor with normal sialic acid content induces platelet aggregation in the absence of ristocetin. Role of platelet activation, fibrinogen, and two distinct membrane receptors.

Authors:  L De Marco; M Mazzuccato; M Grazia Del Ben; U Budde; A B Federici; A Girolami; Z M Ruggeri
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

4.  von Willebrand factor interaction with the glycoprotein IIb/IIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia.

Authors:  L De Marco; A Girolami; T S Zimmerman; Z M Ruggeri
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

5.  Glanzmann thrombasthenia: deficient binding of von Willebrand factor to thrombin-stimulated platelets.

Authors:  Z M Ruggeri; R Bader; L de Marco
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.